Epigenomics of Systemic Autoimmunity

系统性自身免疫的表观基因组学

基本信息

项目摘要

DESCRIPTION (provided by applicant): The overall goal of this application is to establish a program that facilitates translation of groundbreaking epigenetic concepts in lymphocyte biology and their interaction with genetic predisposition into new approaches to the treatment of human autoimmune diseases. This will be achieved by facilitating collaborations between investigators working at the forefront of basic and clinical research through the interconnected projects described in this proposal. This application brings together the extensive resources, scientific talent and clinical expertise at the University of Michigan (UM) to create an Autoimmunity Center of Excellence (ACE) that, together with the collaborating Autoimmunity Centers of Excellence at other institutions, will enhance understanding of autoimmune diseases including systemic lupus erythematosus, as well as rheumatoid arthritis, scleroderma, Sjogren's Syndrome and autoimmune liver diseases. The UM-ACE proposal unites basic groups studying mechanisms of epigenetics and lymphocyte biology with clinical researchers studying the immunology and treatment of these autoimmune diseases. The three basic/translational projects focus on genetic/epigenetic interactions in the development of autoimmunity, and are designed to identify novel mechanisms for targeted therapy. The Principal Project will use state of the art genomic and epigenomic approaches and technology to characterize the impact of exogenous epigenetic modifiers on the T cell epigenome and gene expression in a previously undescribed T cell subset found in patients with systemic lupus erythematosus as well as other forms of systemic autoimmunity. These studies will also identity and test novel therapeutic targets identified in these studies, using in vitro assays. The Pilot Project will compare the size of this subset in patients with other active and inactive autoimmune diseases, including rheumatoid arthritis, scleroderma, Sjogren's Syndrome and autoimmune liver diseases as well as the relationship of the subset to biomarkers of epigenetically relevant environmental exposures in these patients. The collaborative project will define the relationship between the novel T cell subset size, total lupus genetic risk, and the SLEDAI score in patients with inactive and active lupus, and test the presence and size of the subset as a prognostic biomarker for disease progression and remission in a multicenter longitudinal study.
描述(由申请人提供):本申请的总体目标是建立一个项目,促进将淋巴细胞生物学中突破性的表观遗传学概念及其与遗传易感性的相互作用转化为治疗人类自身免疫性疾病的新方法。这将通过本提案中描述的相互关联的项目促进在基础和临床研究前沿工作的研究人员之间的合作来实现。该申请汇集了密歇根大学(UM)的广泛资源、科学人才和临床专业知识,创建了一个卓越的自身免疫中心(ACE),该中心与其他机构的卓越自身免疫中心合作,将加强对自身免疫性疾病的了解,包括系统性红斑狼疮、类风湿性关节炎、硬皮病、干燥综合征和自身免疫性肝病。UM-ACE提案将研究表观遗传学和淋巴细胞生物学机制的基础小组与研究这些自身免疫性疾病的免疫学和治疗的临床研究人员联合起来。这三个基础/转化项目侧重于自身免疫发展中的遗传/表观遗传相互作用,旨在确定靶向治疗的新机制。主要项目将使用最先进的基因组学和表观基因组学方法和技术来表征外源性表观遗传修饰剂对系统性红斑狼疮患者以及其他形式的系统性自身免疫患者中发现的T细胞亚群中T细胞表观基因组和基因表达的影响。这些研究还将使用体外分析方法识别和测试在这些研究中确定的新的治疗靶点。该试点项目将比较这一亚群患者与其他活跃患者的规模

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BRUCE C. RICHARDSON其他文献

BRUCE C. RICHARDSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BRUCE C. RICHARDSON', 18)}}的其他基金

Does Demethylation of the Inactive X Contribute to Lupus in Women?
非活性 X 的去甲基化是否会导致女性狼疮?
  • 批准号:
    8245569
  • 财政年份:
    2011
  • 资助金额:
    $ 69.21万
  • 项目类别:
Does Demethylation of the Inactive X Contribute to Lupus in Women?
非活性 X 的去甲基化是否会导致女性狼疮?
  • 批准号:
    8398943
  • 财政年份:
    2011
  • 资助金额:
    $ 69.21万
  • 项目类别:
Does Demethylation of the Inactive X Contribute to Lupus in Women?
非活性 X 的去甲基化是否会导致女性狼疮?
  • 批准号:
    8597403
  • 财政年份:
    2011
  • 资助金额:
    $ 69.21万
  • 项目类别:
Does Demethylation of the Inactive X Contribute to Lupus in Women?
非活性 X 的去甲基化是否会导致女性狼疮?
  • 批准号:
    8045033
  • 财政年份:
    2011
  • 资助金额:
    $ 69.21万
  • 项目类别:
Pilot Project Program
试点项目计划
  • 批准号:
    9302768
  • 财政年份:
    2011
  • 资助金额:
    $ 69.21万
  • 项目类别:
Pilot Project Program
试点项目计划
  • 批准号:
    9058302
  • 财政年份:
    2011
  • 资助金额:
    $ 69.21万
  • 项目类别:
OGT Overexpression in Women with Lupus
狼疮女性中 OGT 过度表达
  • 批准号:
    7644479
  • 财政年份:
    2008
  • 资助金额:
    $ 69.21万
  • 项目类别:
OGT Overexpression in Women with Lupus
狼疮女性中 OGT 过度表达
  • 批准号:
    7510078
  • 财政年份:
    2008
  • 资助金额:
    $ 69.21万
  • 项目类别:
Aberrant gene expression in CD4+CD28-T cells: mechanisms
CD4 CD28-T 细胞中的异常基因表达:机制
  • 批准号:
    7793487
  • 财政年份:
    2006
  • 资助金额:
    $ 69.21万
  • 项目类别:
Environmental effects on lupus T cell DNA methylation and gene expression
环境对狼疮 T 细胞 DNA 甲基化和基因表达的影响
  • 批准号:
    7645044
  • 财政年份:
    2006
  • 资助金额:
    $ 69.21万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 69.21万
  • 项目类别:
    Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 69.21万
  • 项目类别:
    Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 69.21万
  • 项目类别:
    Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 69.21万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 69.21万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 69.21万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 69.21万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 69.21万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 69.21万
  • 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 69.21万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了